Androgen receptors in early and castration resistant prostate cancer: friend or foe?

Hormones (Athens). 2013 Apr-Jun;12(2):224-35. doi: 10.14310/horm.2002.1406.
No abstract available

Publication types

  • Review

MeSH terms

  • Alternative Splicing
  • Androgen Receptor Antagonists / therapeutic use
  • Androgens / metabolism
  • Animals
  • Antineoplastic Agents / therapeutic use
  • Disease Progression
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Models, Biological*
  • Molecular Targeted Therapy
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm Proteins / chemistry
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / metabolism*
  • Prognosis
  • Prostate / drug effects
  • Prostate / metabolism*
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms, Castration-Resistant / diagnosis
  • Prostatic Neoplasms, Castration-Resistant / drug therapy
  • Prostatic Neoplasms, Castration-Resistant / genetics
  • Prostatic Neoplasms, Castration-Resistant / metabolism*
  • Protein Isoforms / antagonists & inhibitors
  • Protein Isoforms / chemistry
  • Protein Isoforms / genetics
  • Protein Isoforms / metabolism
  • Receptors, Androgen / chemistry
  • Receptors, Androgen / genetics
  • Receptors, Androgen / metabolism*
  • Signal Transduction / drug effects

Substances

  • Androgen Receptor Antagonists
  • Androgens
  • Antineoplastic Agents
  • Neoplasm Proteins
  • Protein Isoforms
  • Receptors, Androgen